THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

If Genzyme is acquired, Termeer gets $23m

CEO’s contract includes change of control terms

Henri Termeer joined Genzyme in 1983. Henri Termeer joined Genzyme in 1983.
By Robert Weisman
Globe Staff / August 11, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Genzyme Corp. chief executive Henri A. Termeer stands to pocket more than $23 million if the Cambridge biotechnology company is sold to French drug maker Sanofi-Aventis SA or another suitor, according to a provision in his contract. (Full article: 700 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass